Literature DB >> 24269855

Continuous ultrafiltration for congestive heart failure: the CUORE trial.

Giancarlo Marenzi1, Manuela Muratori2, Eugenio R Cosentino3, Elisa R Rinaldi4, Valeria Donghi2, Valentina Milazzo2, Emiliana Ferramosca4, Claudio Borghi3, Antonio Santoro4, Piergiuseppe Agostoni5.   

Abstract

BACKGROUND: There are limited data comparing ultrafiltration with standard medical therapy as first-line treatment in patients with severe congestive heart failure (HF). We compared ultrafiltration and conventional therapy in patients hospitalized for HF and overt fluid overload. METHODS AND
RESULTS: Fifty-six patients with congestive HF were randomized to receive standard medical therapy (control group; n = 29) or ultrafiltration (ultrafiltration group; n = 27). The primary end point of the study was rehospitalizations for congestive HF during a 1-year follow-up. Despite similar body weight reduction at hospital discharge in the 2 groups (7.5 ± 5.5 and 7.9 ± 9.0 kg, respectively; P = .75), a lower incidence of rehospitalizations for HF was observed in the ultrafiltration-treated patients during the following year (hazard ratio 0.14, 95% confidence interval 0.04-0.48; P = .002). Ultrafiltration-induced benefit was associated with a more stable renal function, unchanged furosemide dose, and lower B-type natriuretic peptide levels. At 1 year, 7 deaths (30%) occurred in the ultrafiltration group and 11 (44%) in the control group (P = .33).
CONCLUSIONS: In HF patients with severe fluid overload, first-line treatment with ultrafiltration is associated with a prolonged clinical stabilization and a greater freedom from rehospitalization for congestive HF.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Congestion; diuretics; heart failure; ultrafiltration

Mesh:

Substances:

Year:  2013        PMID: 24269855     DOI: 10.1016/j.cardfail.2013.11.004

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  17 in total

1.  Gaps in the Heart Failure Guidelines.

Authors:  Bao Tran; Gregg C Fonarow
Journal:  Card Fail Rev       Date:  2015-04

Review 2.  Gaps in the Heart Failure Guidelines.

Authors:  Bao Tran; Gregg C Fonarow
Journal:  Eur Cardiol       Date:  2014-12

Review 3.  [Cardio-renal axis : Relationship of heart failure and renal insufficiency as comorbidities].

Authors:  M Zeisberg; M J Koziolek
Journal:  Internist (Berl)       Date:  2018-05       Impact factor: 0.743

Review 4.  Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome.

Authors:  Yoshitsugu Obi; Taehee Kim; Csaba P Kovesdy; Alpesh N Amin; Kamyar Kalantar-Zadeh
Journal:  Cardiorenal Med       Date:  2015-11-06       Impact factor: 2.041

Review 5.  Defining the role of ultrafiltration therapy in acute heart failure: a systematic review and meta-analysis.

Authors:  Ankur Jain; Nikhil Agrawal; Amir Kazory
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

Review 6.  The dark side of the kidney in cardio-renal syndrome: renal venous hypertension and congestive kidney failure.

Authors:  Pierpaolo Di Nicolò
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

Review 7.  [Renal dysfunction in heart failure and hypervolumenia : Importance of congestion and backward failure].

Authors:  W Druml
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-05-10       Impact factor: 0.840

Review 8.  The acute cardiorenal syndrome type I: considerations on physiology, epidemiology, and therapy.

Authors:  Ali A Valika; Maria Rosa Costanzo
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 9.  Ultrafiltration for acute heart failure.

Authors:  Mehul Srivastava; Nicholas Harrison; Ana Francisca Sma Caetano; Audrey R Tan; Mandy Law
Journal:  Cochrane Database Syst Rev       Date:  2022-01-21

Review 10.  Extracorporeal ultrafiltration for acute heart failure: patient selection and perspectives.

Authors:  Valentina Milazzo; Nicola Cosentino; Giancarlo Marenzi
Journal:  Vasc Health Risk Manag       Date:  2017-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.